ArticleBMC endocrine disorders2025
Trends of metabolic syndrome among Iranian patients with diabetes and its association with cardiovascular disease and diabetes complications: a nationwide study of the National Program for Prevention and Control of Diabetes.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMetabolic syndrome (MetS) is highly prevalent among individuals with type 2 diabetes and is characterized by a combination of specific clinical parameters including abnormal blood lipid levels, impaired fasting glucose, elevated blood pressure, and excessive abdominal fat. This study aimed to investigate the trends in MetS prevalence and its components among patients with diabetes in Iran from 2015 to 2021 and explore its association with cardiovascular disease and diabetes complications.
methodsWe conducted a nationwide trend analysis using data from 313,939 patients with diabetes enrolled in the National Program for Prevention and Control of Diabetes (NPPCD). Annual trends of Mets according to age and gender, annual trends of MetS components and the association between MetS and CVD, diabetic foot, neuropathy, nephropathy, and retinopathy were analyzed using SPSS version 26.
resultsOverall, the prevalence of MetS in patients with diabetes increased from 60.3% in 2015 to 66.9% in 2021, with a total prevalence of 63.2%. Women (67.4%) and the 50-60 age group (66.0%) exhibited the highest rates. Among MetS components, fasting blood glucose > 100 mg/dL had the highest prevalence (89.5%), followed by low HDL (61.8%) and obesity (49.8%). AORs of association between MetS and cardiovascular disorder, diabetic foot, retinopathy, nephropathy, and neuropathy were 1.826 (1.670-1.998), 1.343 (1.145-1.576), 1.376 (1.263-1.500), 1.587 (1.434-1.757), 1.613 (1.499-1.736), respectively.
conclusionPrevalent cases of MetS among patients with diabetes in Iran and positive associations between MetS and cardiovascular disorder and diabetes complications highlights the need for targeted interventions focusing on glycemic control, obesity management, screening, health education, and better diabetic management, especially in high-risk groups. Future research should explore the impact of lifestyle modifications and policy-driven interventions in reducing MetS-related complications.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.